August 29, 2014 9:40 PM ET

Capital Markets

Company Overview of EQT Partners AB

Company Overview

EQT Partners AB is a private equity and venture capital firm specializing in expansion capital, mid venture, growth financing, buyouts, growth equity, middle market, industry consolidation, public-to private transactions, mezzanine financing, special situations including stressed and distressed situations; illiquid, and secondary investments. The firm also invests infrastructure with a focus on basic infrastructure, concession-based infrastructure, and infrastructure-related services; and debt of over-leveraged companies. The firm also seeks to invest in the industrials, healthcare, energy, environment, retail, business services, technology, media, and telecommunications sector. It prefers t...

Hovslagargatan 3

Stockholm,  111 48


Founded in 1994


46 8 50 65 53 00


46 8 50 65 53 19

Key Executives for EQT Partners AB

Chief Executive Officer
Founding Partner
Age: 48
Age: 46
Head of Finance and Chief Financial Controller
Compensation as of Fiscal Year 2014.

EQT Partners AB Key Developments

EQT Partners May Sell Or List Granngården

EQT Partners AB is rumoured to be planning to divest its portfolio company Granngården AB. According to Mergermarket sources, EQT is studying either an auction or a public listing for the company. Nordea is to manage the divestment, according to sources.

Five Companies Interested In Cheminova

Bain Capital, LLC, CVC Capital Partners Limited, EQT Partners AB, ADAMA Agricultural Solutions Ltd. and FMC Corp. (NYSE:FMC) are interested in acquiring Cheminova A/S, owned by Auriga Industries A/S (CPSE:AURI B), Berlingske Tidende reported.

Nobel Biocare Said To Draw Interests

Nobel Biocare Holding AG (SWX:NOBN) ) that’s exploring a sale, has attracted interest from potential buyers including EQT Partners AB and Danaher Corp. (NYSE:DHR), said people with knowledge of the matter. Nobel Biocare was initially approached by EQT with an offer of about CHF 17 a share, which would have valued the company at about CHF 2.1 billion said the people, who asked not to be identified because talks are private. The offer prompted Nobel Biocare and its adviser Goldman Sachs Group Inc. (GS) to invite other bids as it seeks a higher price, the people said. Other companies such as DENTSPLY International Inc. (NasdaqGS:XRAY) and buyout firms are also expected to look at Nobel Biocare, the people said. Potential buyers include Straumann Holding AG (SWX:STMN), Sirona Dental Systems Inc., Johnson & Johnson (NYSE:JNJ), Medtronic, Inc. (NYSE:MDT), Zimmer Holdings, Inc. (NYSE:ZMH), Henry Schein, Inc. (NasdaqGS:HSIC), and 3M Company (NYSE:MMM), according to a note on July 30 from Lisa Bedell Clive, a London-based analyst at Sanford C. Bernstein & Co. Nobel Biocare could sell for as much as CHF 18 a share, she said in the note.

Similar Private Companies By Industry

Company Name Region
Svenska Metallborsen Europe
Lazard AB Europe
Tamm & Partners AB Europe
NASDAQ OMX Clearing AB Europe
Swedbank Corporate Finance Europe

Recent Private Companies Transactions

July 29, 2014
Bureau van Dijk Electronic Publishing BV
July 24, 2014
Dataflow Verification Services Limited
July 2, 2014
Ventelo AS

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EQT Partners AB, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at